Trial Profile
Study to evaluate the effectiveness and safty of the mFOLFOX+bevacizumab combination therapy for bladder adenocarcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Oct 2020
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Fluorouracil; Levofolinic acid; Oxaliplatin
- Indications Bladder cancer
- Focus Therapeutic Use
- 08 Oct 2020 Status changed from recruiting to completed.
- 31 May 2016 New trial record